BSF Enterprise drops 10.56% as Indigo Capital debt conversion triggers dilution

Health Pharma & Biotech Written by: Ian Lyall 09:30 Tue 25 Aug 2026 --> Edited by: Jamie Ashcroft Disclaimer No investment advice About this content Editorial Standards & Policies Share article About this content × About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business output at the Daily... Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. Proactive news team spans the world’s key finance and investing hubs with bureaus and studios in London, New York, Toronto, Vancouver, Sydney and Perth. We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. Use of technology Proactive has always been a forward looking and enthusiastic technology adopter. Our human content creators are equipped with many decades of valuable expertise and experience. The team also has access to and use technologies to assist and enhance workflows. Proactive will on occasion use automation and software tools, including generative AI. Nevertheless, all content published by Proactive is edited and authored by humans, in line with best practice in regard to content production and search engine optimisation. BSF Enterprise PLC ( LSE:BSFA OTC:BSFAF ) View Price & Profile BSF Enterprise drops 10.56% as Indigo Capital debt conversion triggers dilution Published: 09:30 25 Aug 2026 BST BSF Enterprise PLC (LSE:BSFA, OTC:BSFAF) lost ground on Tuesday after a debt conversion sparked equity dilution concerns across its shareholder base. The tissue engineering, lab-grown materials, and bioactive solutions developer fell 10.56% to 1.12p in morning London trade as the market absorbed the planned arrival of new shares. At the heart of the decline is a formal conversion notice from Indigo Capital Investments regarding the company's £1 million convertible loan note instrument. That notice requires the business to issue 10,000,000 new ordinary shares of 1 penny each to satisfy £100,283 of the outstanding debt balance. Compounding the dilution pressure, the group confirmed that an application will be made for the new shares to enter the Equity Shares transition category of the Official List. Official admission and dealings on the London Stock Exchange's main market for listed securities are scheduled to become effective at 8.00 a.m. on 28 August 2026. The new equity will rank equally in all respects with existing stock, expanding the company's issued share capital and total voting rights to 203,749,437 ordinary shares. In its regulatory disclosure, the group confirmed that the market filing contained inside information under domestic market abuse legislation. Hanging over any near-term share price recovery is the remaining £899,717 debt balance under the loan facility, which carries the continuing risk of further equity dilution if converted. Continue reading